⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19966539 | 0.85 | — | — | |
| SCHEMBL19169880 | 0.78 | — | — | |
| SCHEMBL22097890 | 0.76 | — | — | |
| SCHEMBL22729206 | 0.73 | — | — | |
| SCHEMBL14865390 | 0.70 | — | — | |
| SCHEMBL19513480 | 0.67 | — | — | |
| SCHEMBL18386480 | 0.65 | — | — | |
| SCHEMBL16437543 | 0.63 | — | — | |
| SCHEMBL1933279 | 0.63 | — | — | |
| SCHEMBL10745554 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | BIOVENTURES, LLC | 2024-02-29 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11746117-B2 | Heterocyclic compound and organic light emitting device comprising same | LG CHEM, LTD. (KR) | 2023-09-05 | — | — | US | disclosed |
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20230167087-A1 | 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230121807-A1 | NITRILE DERIVATIVE THAT ACTS AS INHIBITOR OF DIPEPTIDYL PEPTIDASE 1 AND USE THEREOF | HAISCO PHARMACEUTICALS PTE. LTD (SG) | 2023-04-20 | — | — | US | disclosed |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-2860181-B1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-10189850-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2994467-B1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2018-08-01 | — | — | EP | disclosed |
| US-20180201618-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| WO-2018125799-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018095344-A1 | ISOCITRATE DEHYDROGENASE (IDH) INHIBITOR | SHANGHAI METON PHARMACEUTICAL CO., LTD (CN) | 2018-05-31 | — | — | WO | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| WO-2018045957-A1 | CDK4/6 INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2018-03-15 | — | — | WO | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-9815817-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |